Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.42 |
| ▸ | DHODH | Q02127 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3799818 | 0.87 | NPC1 (0.68) | NPC1ALDH1A1RAB9APKML3MBTL1 | |
| SCHEMBL13481452 | 0.82 | ALDH1A1 (0.53) | NPC1ALDH1A1RAB9APKML3MBTL1 | |
| SCHEMBL541771 | 0.82 | PDE5A (0.57) | NPC1ALDH1A1RAB9APKML3MBTL1 | |
| SCHEMBL10740426 | 0.75 | HDAC3 (0.53) | NPC1ALDH1A1RAB9APKML3MBTL1 | |
| SCHEMBL31289535 | 0.75 | ALDH1A1 (0.51) | NPC1ALDH1A1RAB9APKML3MBTL1 | |
| SCHEMBL21975923 | 0.75 | NPC1 (0.62) | NPC1ALDH1A1RAB9APKML3MBTL1 | |
| SCHEMBL10740825 | 0.74 | F7 (0.55) | NPC1ALDH1A1RAB9APKML3MBTL1 | |
| SCHEMBL10740903 | 0.74 | NPC1 (0.42) | NPC1ALDH1A1RAB9APKML3MBTL1 | |
| SCHEMBL11947495 | 0.74 | MGAM (0.48) | NPC1ALDH1A1RAB9APKML3MBTL1 | |
| SCHEMBL13481845 | 0.73 | NPC1 (0.49) | NPC1ALDH1A1RAB9APKML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010081145-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLAXOSMITHKLINE LLC (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010081149-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLAXOSMITHKLINE LLC (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20100029655-A1 | Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them | LEIVERS MARTIN ROBERT | 2010-02-04 | — | — | US | disclosed |
| WO-2010006096-A1 | PROCESSES FOR THE PREPARATION OF ANTI-VIRAL COMPOUNDS AND COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009111501-A1 | DERIVATIVES OF IMIDAZO [4, 5-D] PYRIDAZINE AND THEIR USE AS ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090197880-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197880-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HAVCR2, SARS1, RPL35 | NPC1 228/4885ALDH1A1 2251/4885RAB9A 2101/4885 |
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | MAVS, SARS1, HAVCR2 | NPC1 240/4885ALDH1A1 2203/4885RAB9A 1850/4885 |
| US-20100029655-A1 | Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them | RPL35, HAVCR2, RPL5 | NPC1 1585/4885ALDH1A1 3020/4885RAB9A 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.